Detecting Markers of Therapy-Induced Senescence in Cancer Cells.
Therapy-induced senescence (TIS), a lasting chemotherapy-evoked proliferative arrest of tumor cells, has gained increasing attention by cancer researchers because of its' profound biological implications, and by clinical oncologists due to its potential contribution to the long-term outcome of cancer patients post-treatment. Although both apoptosis and senescence represent therapy-inducible, ultimate cell-cycle exit programs, mediated via DNA damage response signaling, apoptotic cell death as the faster and often quantitatively more prominent tumor response has been in the scientific focus for decades. The more recently recognized TIS as another "safeguard" response of cancer cells that were never primed for or failed to execute apoptosis, not only reflects a more complex "arrest-plus-other features" cell-autonomous condition but produces non-cell-autonomous phenotypes at the tumor site, collectively impinging on tumor control and clinical outcome. Hence, TIS research is gaining pivotal interest from both a tumor biological and a therapeutic perspective, and the development of non-DNA damaging, senescence-evoking therapeutics is about to become a major research objective. In this chapter, we describe a well-characterized, genetically controlled TIS model system based on primary BCL2-expressing Eμ-myc transgenic lymphoma cells harboring defined genetic lesions and provide protocols for co-staining of either senescence-associated β-galactosidase (SA-β-gal) activity or trimethylated lysine 9 of histone H3 (H3K9me3) together with Ki67 to detect the senescent status of therapy-exposed cancer cells.
Department of Hematology, Oncology and Tumor Immunology, Campus Virchow Clinic, Charité-University Medical Center, Berlin, Germany.
Dorothy N Y
DN
Fan
Department of Hematology, Oncology and Tumor Immunology, Campus Virchow Clinic, Charité-University Medical Center, Berlin, Germany. clemens.schmitt@charite.de.|Molekulares Krebsforschungszentrum-MKFZ, Berlin, Germany. clemens.schmitt@charite.de.|Max-Delbrück-Center for Molecular Medicine, Robert-Rössle-Str. 10, Berlin, 13125, Germany. clemens.schmitt@charite.de.
Clemens A
CA
Schmitt
D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D015415:Biomarkers; D045744:Cell Line, Tumor; D016922:Cellular Senescence / Q000187:drug effects / Q000235:genetics; D042002:Chromatin Assembly and Disassembly; D004249:DNA Damage / Q000187:drug effects / Q000235:genetics; D005786:Gene Expression Regulation / Q000187:drug effects; D055879:Gene Knock-In Techniques; D006570:Heterochromatin / Q000235:genetics / Q000378:metabolism; D006657:Histones / Q000378:metabolism; D006801:Humans; D007150:Immunohistochemistry; D019394:Ki-67 Antigen / Q000235:genetics / Q000378:metabolism; D001616:beta-Galactosidase / Q000378:metabolism
D000970:Antineoplastic Agents; D015415:Biomarkers; D006570:Heterochromatin; D006657:Histones; D019394:Ki-67 Antigen; D001616:beta-Galactosidase
Cancer; Chemotherapy; DNA damage response; H3K9me3; Heterochromatin; Ki67; SA-β-gal; Senescence markers; Senescence-associated β-galactosidase; TIS model system; Therapy-induced senescence (TIS)